

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

APC anti-mouse Perforin

RRID:AB_2721465

Type: Antibody

Proper Citation

BioLegend Cat# 154404, RRID:AB_2721465

Antibody Information

URL: http://antibodyregistry.org/AB_2721465

Proper Citation: BioLegend Cat# 154404, RRID:AB_2721465

Target Antigen: Perforin

Host Organism: rat

Clonality: monoclonal

Comments: Applications: ICFC

Antibody Name: APC anti-mouse Perforin

Description: This monoclonal targets Perforin

Target Organism: mouse

Clone ID: Clone S16009B

Antibody ID: AB_2721465

Vendor: BioLegend

Catalog Number: 154404

Alternative Catalog Numbers: 154403

Record Creation Time: 20231110T033728+0000

Record Last Update: 20260829T055851+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-mouse Perforin.

No alerts have been found for APC anti-mouse Perforin.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Lei G, et al. (2026) Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. *Cell*.

Bashir H, et al. (2026) Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth. *Cancer cell*, 44(7), 1458.

Zhang SW, et al. (2026) Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment. *Cell*, 189(4), 1039.

Xu Y, et al. (2026) Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy. *Cell reports. Medicine*, 7(3), 102659.

Li A, et al. (2026) 5-HT reuptake blockade induces pyroptosis in BRAFV600E-mutated melanomas via remodeling histone serotonylation. *Cell reports. Medicine*, 102537.

Li A, et al. (2025) Lactylation of LSD1 is an acquired epigenetic vulnerability of BRAFi/MEKi-resistant melanoma. *Developmental cell*, 60(14), 1974.

Katkeviciute E, et al. (2025) Bacteria-derived 3-hydroxydodecanoic acid induces a potent anti-tumor immune response via the GPR84 receptor. *Cell reports*, 44(3), 115357.

Xiao Y, et al. (2025) HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer. *Cell metabolism*.

Wu SY, et al. (2023) CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. *Med (New York, N.Y.)*, 4(6), 373.

Yang F, et al. (2023) Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. *Cell metabolism*, 35(1), 84.

Walker JA, et al. (2019) Polychromatic Reporter Mice Reveal Unappreciated Innate Lymphoid Cell Progenitor Heterogeneity and Elusive ILC3 Progenitors in Bone Marrow. *Immunity*, 51(1), 104.